Patent intelligence · US
US 6420134
Vaccines for nontypable haemophilus influenzae
Vaccines for nontypable haemophilus influenzae
Patent details — US 6420134
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 16, 2002
- Expiration
- Jul 11, 2022
- Applicant
- Praxis Biologics, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K39/00, A61P, A61P31/00
Quick answer
US 6420134 (Vaccines for nontypable haemophilus influenzae) is held by Praxis Biologics, Inc.. Status: expired. Granted Jul 16, 2002. Expires Jul 11, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Praxis Biologics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K39/00, A61P, A61P31/00, A61P31/04
More from Praxis Biologics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Frequently asked questions
What is US patent 6420134?
US 6420134 (Vaccines for nontypable haemophilus influenzae) is held by Praxis Biologics, Inc.. Status: expired. Granted Jul 16, 2002. Expires Jul 11, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6420134?
Praxis Biologics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 6420134 expire?
Our index shows an expiration date of Jul 11, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.